Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

…, E Pizzichini, J Reid, A Veale, L Grönke… - European …, 2015 - Eur Respiratory Soc
Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with
the mono-components was evaluated in patients with moderate to very severe chronic …

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active …

…, AR Anzueto, K Carter, L Grönke… - The Lancet …, 2018 - thelancet.com
Background Combinations of long-acting bronchodilators are recommended to reduce the
rate of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear whether …

[HTML][HTML] Tiotropium+ olodaterol shows clinically meaningful improvements in quality of life

D Singh, GT Ferguson, J Bolitschek, L Grönke… - Respiratory …, 2015 - Elsevier
Background Tiotropium + olodaterol improves lung function and symptoms compared to
monotherapies in chronic obstructive pulmonary disease (COPD). The OTEMTO 1 and 2 studies …

[HTML][HTML] The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

…, J Westerman, AM Kirsten, J Hébert, L Grönke… - Pulmonary …, 2015 - Elsevier
Background This study investigated the effects on 24-h lung function and lung volume of a
once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium …

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® …

…, E Derom, J Echave-Sustaeta, L Grönke… - … journal of chronic …, 2016 - Taylor & Francis
Background Tiotropium + olodaterol has demonstrated improvements beyond lung function
benefits in a large Phase III clinical program as a once-daily maintenance treatment for …

[HTML][HTML] Efficacy of tiotropium+ olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis

…, M Fležar, S Korn, L Korducki, L Grönke… - Advances in …, 2015 - Springer
Introduction The once-daily long-acting muscarinic antagonist (LAMA) tiotropium and once-daily
long-acting β 2 -agonist (LABA) olodaterol have been studied as a once-daily fixed-…

[HTML][HTML] Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies

D Singh, M Gaga, O Schmidt, L Bjermer, L Grönke… - Respiratory …, 2016 - Springer
Background As lung function declines rapidly in the early stages of chronic obstructive
pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease and …

[HTML][HTML] β-Blockers in COPD: a cohort study from the TONADO Research Program

F Maltais, R Buhl, A Koch, VC Amatto, J Reid, L Grönke… - Chest, 2018 - Elsevier
Background Cardiovascular disease is a frequent comorbidity in patients with COPD. Many
physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (…

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the …

…, H Taniguchi, A Takizawa, L Grönke… - … Journal of Chronic …, 2016 - Taylor & Francis
Full article: The efficacy and safety of combined tiotropium and olodaterol via the Respimat®
inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® …

[HTML][HTML] Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies

…, N Bennett, E Clerisme-Beaty, L Grönke… - NPJ primary care …, 2017 - nature.com
Chronic obstructive pulmonary disease is associated with significant morbidity and mortality.
Trials of maintenance chronic obstructive pulmonary disease treatments focus on …